IIA

The IIA Releases New Global Internal Audit Standards to Lead Profession into the Future

Retrieved on: 
Tuesday, January 9, 2024
CIA, Volunteering, Research, International, Feedback, CPA, Institute of Internal Auditors, IIA, CGMA, CITP, Organization, Public sector, News, Education, Audit

LAKE MARY, Fla., Jan. 9, 2024 /PRNewswire/ -- The Institute of Internal Auditors (The IIA) – the internal audit profession's leader in standards, certifications, education, research, and technical guidance worldwide – today released its new Global Internal Audit Standards™.

Key Points: 
  • "The new Global Internal Audit Standards meet an urgent professional and marketplace need," said Anthony Pugliese, CIA, CPA, CGMA, CITP, President and CEO of The IIA.
  • The Global Internal Audit Standards become effective in January 2025, 12 months after their release, though The IIA encourages early adoption.
  • "Today's release of the new Global Internal Audit Standards is a tremendous milestone for the internal audit profession," said Naohiro Mouri, CIA, CPA, chairman of the International Internal Audit Standards Board (IIASB).
  • A free webinar – Get to Know the Global Internal Audit Standards – is being offered to IIA members and nonmembers on January 24.

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Fungal infection, Liver, Marketing, Chills, INN, Risk, Leukopenia, Hypotension, Fungus, Hypertension, Nausea, DNA, Inflammation, Liver disease, Anatomy, IIA, CHMP, Diarrhea, Fever, Infection, ATC, Hepatomegaly, European, Neutrophil, Neoplasm, HIV, Tachycardia, Anemia, Hypocalcemia, Hypokalemia, Patient, Medical Subject Headings, Caspofungin, European Commission, Echinocandin, Kidney failure, International, Bilirubin, Neutropenia, Blood, Language, Thrombocytopenia, Magnesium, Select, Medicine, Vomiting, Phlebitis, Amphotericin B, Allergy, Fluconazole, Headache, Rat, Haematopoiesis, Committee, Checklist, Alkaline phosphatase, Rash, Medical device

Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Medical Subject Headings, Hip, Marketing, European Commission, Shoulder, MRI, INN, Fatigue, Movement, Dopamine, ATC, Allergy, International, European, Headache, Disease, Weakness, Syndrome, Nausea, Language, Brain, Somnolence, Dizziness, L-DOPA, Ropinirole, Restless legs syndrome, Abdomen, Red, Parkinson's disease, Thigh, Select, Committee, Patient, Cell, Time, Pramipexole, Anatomy, Medicine, Vomiting, IIA, Magnetic resonance imaging, CHMP, Skin, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Blood pressure, Patient, Medical Subject Headings, Marketing, European Commission, Agency, INN, Weight, Constipation, Risk, ATC, Weight loss, Blood, International, Diet, BMI, European, Diabetes, Method, Nausea, Language, Brain, Bupropion, Heart, Dizziness, Naltrexone, Body mass index, Appetite, Food, Kidney, Tablet, Interim, Xerostomia, Select, Human, Safety, Risk management, Anatomy, Medicine, Seizure, Pleasure, Vomiting, IIA, CHMP, Exercise, Medical device

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Medical Subject Headings, Diarrhea, Marketing, Platinum, INN, Peritoneum, Constipation, Fatigue, Woman, Ovarian cancer, ATC, Insomnia, Hypertension, Capsule, International, Cough, Tubing (recreation), Weakness, Headache, Disease, Nausea, Neutropenia, Language, DNA, Mouth, Cancer, Neoplasm, Thrombocytopenia, Abdomen, Dizziness, Platelet, PARP, Neutrophil, Appetite, European Medicines Agency, Back pain, Uterus, Enzyme, Select, Cell, Patient, Time, Safety, Anatomy, Anemia, Arthralgia, Vomiting, IIA, Periodic breathing

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Medical Subject Headings, Marketing, Diplopia, Agency, INN, Risk, ATC, International, Population, Headache, Ageing, Nausea, Sodium, Brain, Language, Mouth, Seizure, Dizziness, European Medicines Agency, Nervous system, Tablet, Select, Safety, Generalized tonic–clonic seizure, Anatomy, IIA, Carbamazepine, Medical device

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Kidney, Metabolic acidosis, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Blood pressure, Medical Subject Headings, Marketing, CYP2C9, Agency, INN, Immune system, Lymph, Woman, Movement, Allergy, Heart rate, ATC, Multiple sclerosis, Cryptococcosis, Hypertension, International, Spinal cord, Disease, Headache, Parent, Blood, Language, SPMS, Brain, Cancer, Inflammation, Stroke, Liver, Cardiology, DSM-IV codes, Pregnancy, European Medicines Agency, Lymphocyte, Infection, Tablet, EDSS, EMEA, Select, Cell, Patient, Birth, Checklist, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised